ArticleStroke and vascular neurology2026
Chinese expert consensus on the treatment and diagnosis of moyamoya disease and moyamoya syndrome (2024).
Article in Stroke and vascular neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimMoyamoya disease (MMD) is a chronic, occlusive cerebrovascular disorder with no unified management guidelines. This consensus aims to provide updated, evidence-based recommendations for the diagnosis and treatment of MMD.
methodsWe integrated recent findings from epidemiology, genetics and imaging studies-particularly those published since 2017-along with expert input from over 20 clinical centres. Advances in diagnostic criteria, treatment strategies and perioperative management were reviewed and incorporated to update the 2017 consensus.
resultsRefinements in diagnosis include high-resolution imaging and revised Suzuki staging supplemented by new collateral circulation grading. Treatment strategies emphasise individualised surgical planning, especially extracranial-intracranial bypass, and pharmacological management targeting ischaemic events, cognitive decline and collateral vessel formation. Perioperative care focuses on managing complications such as transient neurological dysfunction and stroke through haemodynamic monitoring and timely imaging.
conclusionsThis updated consensus underscores the value of early diagnosis using advanced imaging, personalised interventions and standardised perioperative care. This initiative aims to enhance clinical outcomes and health-related quality of life in MMD patients, offering a contemporary, evidence-based approach to managing MMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.